Biotech Values

[cbfromli]

GTC Biotherapeutics Announces Filing of Shelf Registration Statement
Friday October 21, 8:30 am ET


FRAMINGHAM, Mass.--(BUSINESS WIRE)--Oct. 21, 2005--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that it has filed a universal shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC) pursuant to which the Company may issue up to an aggregate of $50 million of common stock, debt securities, and other types of securities. Proceeds from any offering under the shelf registration statement would provide flexibility in financing GTC's business needs, including funding for development and commercialization of its products and clinical programs as well as for general corporate purposes. The terms and price of any future offerings would be established at the time of the offering.


The shelf registration statement, when declared effective by the SEC, would enable GTC to raise funds from the offering of stock and debt securities covered by the shelf registration statement from time to time and through one or more methods of distribution, subject to market conditions and GTC's capital needs.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

A copy of the preliminary prospectus included in the registration statement may be obtained at the SEC's website at www.sec.gov, through the Investor Relations section of the GTC website at www.gtc-bio.com or via written request to GTC Biotherapeutics, 175 Crossing Blvd., Framingham, MA 01702, Attention: Investor Relations.

GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline and a portfolio of external program production opportunities. GTC's lead program is ATryn®, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATryn® in patients with a hereditary antithrombin deficiency. In addition to the lead ATryn® program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. Additional information is available on the GTC web site, http://www.gtc-bio.com.



--------------------------------------------------------------------------------
Contact:
GTC Biotherapeutics, Inc.
Thomas E. Newberry, 508-370-5374
or
Feinstein Kean Healthcare
Francesca DeVellis, 617-577-8110 (investors)